Chronic thromboembolic pulmonary hypertension (CTEPH) is classified as group IV pulmonary hypertension, characterized by thrombotic occlusion of the pulmonary arteries leading to vascular stenosis or obstruction, progressive increase in pulmonary vascular resistance and pulmonary arterial pressure, and eventual right heart failure. Unlike other types of pulmonary hypertension, the prognosis of CTEPH can be significantly improved by surgery, vascular intervention, and/or targeted drug therapy. Pulmonary endarterectomy (PEA) is the preferred treatment of choice for CTEPH. However, PEA is an invasive procedure with high operative risks, and is currently only performed in a few centers in China. Balloon pulmonary angioplasty (BPA) is an emerging interventional technique for CTEPH, serving as an alternative for patients who are ineligible for PEA or with residual pulmonary hypertension after PEA. BPA is gaining traction in China, but its widespread adoption is limited due to its complexity, operator skills, and equipment requirements, a lack of standard operating procedures and technical guidance, which limit the further improvement and development of BPA in China. To address this, a multidisciplinary panel of experts was convened to develop the Consensus on the Procedure of Balloon Pulmonary Angioplasty for the Chronic Thromboembolic Pulmonary Hypertension, which fomulates guidelines on BPA procedural qualification, perioperative management, procedural planning, technical approach, and complication prevention, with the aim of providing recommendations and clinical guidance for BPA treatment in CTEPH and standardizing its clinical application in this setting. Summary of recommendations: Recommendation 1: It is recommended that physicians who specialize in pulmonary vascular diseases take the lead in formulating the diagnostic and treatment plans for CTEPH, using a multidisciplinary approach.Recommendation 2: Training in BPA technique is critical; novice operators should undergo standardized operative training with at least 50 procedures under the guidance of experienced physicians before embarking on independent BPA procedures.Recommendation 3: BPA requires catheterization labs, angiography systems, standard vascular interventional devices and consumables, drugs, and emergency equipment.Recommendation 4: Patient selection for BPA should consider cardiac and pulmonary function, coagulation status, and comorbid conditions to determine indications and contraindications, thereby optimizing the timing of the procedure and improving safety.Recommendation 5: In experienced centers, patients deemed likely to benefit from early BPA, based on clinical and imaging features of CTEPH and without elevated D-dimer levels, could bypass standard 3-month anticoagulation therapy.Recommendation 6: BPA is a complex interventional treatment that requires thorough pre-operative assessment and preparation.Recommendation 7: The use of perioperative anticoagulants in BPA requires a comprehensive risk assessment of intraoperative bleeding by the operator for individualized decision making.Recommendation 8: A variety of venous access routes are available for BPA; unless contraindicated, the right femoral vein is usually preferred because of its procedural convenience and reduced radiation exposure.Recommendation 9: For the different types of vascular lesion in CTEPH, treatment of ring-like stenoses, web-like lesions, and subtotal occlusions should be prioritized before addressing complete occlusions and tortuous lesions, in order to reduce complications and improve procedural safety.Recommendation 10: A targeted, incremental balloon dilatation strategy based on vascular lesions is recommended for BPA.Recommendation 11: Intravascular pulmonary artery imaging technologies, such as OCT and IVUS can assist in accurate vessel sizing and confirmation of wire placement in the true vascular lumen. Pressure wires can be used to objectively assess the efficacy of dilatation during BPA.Recommendation 12: Endpoints for BPA treatment should be individually assessed, taking into account improvements in clinical symptoms, hemodynamics, exercise tolerance, and quality of life.Recommendation 13: Post-BPA routine monitoring of vital signs is essential; anticoagulation therapy should be initiated promptly post-procedure in the absence of complications. In cases of intraoperative hemoptysis, postoperative anticoagulation regimen adjustments should be adjusted according to the bleeding severity.Recommendation 14: If reperfusion pulmonary edema occurs during or after BPA, ensure adequate oxygenation, diuresis, and consider non-invasive positive-pressure ventilation if necessary, while severe cases may require early mechanical ventilation assistance or ECMO.Recommendation 15: In cases of intraoperative hemoptysis, temporary balloon occlusion to stop bleeding is recommended, along with protamine to neutralize heparin. Persistent bleeding may warrant the use of gelatin sponges, coil embolization, or covered stent implantation.Recommendation 16: For contrast imaging during BPA, non-ionic, low or iso-osmolar contrast agents are recommended, with hydration status determined by the patient's clinical condition, cardiac and renal function, and intraoperative contrast volume used.
慢性血栓栓塞性肺动脉高压(chronic thromboembolic pulmonary hypertension,CTEPH)是以肺动脉血栓机化致血管狭窄或闭塞,肺血管阻力和肺动脉压力进行性升高,最终导致右心功能衰竭为特征的一类疾病,属于肺动脉高压的第4大类。不同于其他类型肺动脉高压,CTEPH可以通过外科手术、血管介入和(或)靶向药物治疗显著改善预后。肺动脉内膜剥脱术(pulmonary endarterectomy,PEA)是CTEPH的首选治疗方法。但其创伤较大、手术风险较高,目前国内仅有少数中心开展。经皮肺动脉球囊成形术(balloon pulmonary angioplasty,BPA)是近年迅速发展的肺动脉介入治疗技术,可作为不适合PEA或PEA术后残余肺动脉高压患者的治疗选择。目前BPA在我国兴起,但由于其操作较复杂,且对术者技术水平和医院设备有一定要求,国内尚缺乏统一的BPA操作规程和技术指导,从而限制国内BPA技术的进一步提升与发展。基于此,为进一步规范和推广BPA技术,经过多学科专家研讨和德尔菲专家论证,工作组牵头制定了《经皮肺动脉球囊成形术治疗慢性血栓栓塞性肺动脉高压操作规程专家共识》,针对BPA操作准入标准、围手术期管理、手术规划、技术方法、并发症防治等诸多方面进行了阐述,以期为BPA治疗CTEPH提供推荐意见和临床指导,规范BPA在CTEPH治疗中的临床应用。 经皮肺动脉球囊成形术治疗慢性血栓栓塞性肺动脉高压操作规程推荐意见: 推荐意见1:建议以从事肺血管疾病诊治工作的医师为主导,多学科协作制定CTEPH的诊治方案。推荐意见2:开展BPA技术培训至关重要,对于初学的操作者,建议在有BPA经验的医师指导下完成至少50例次的标准化操作培训,才可以独立开展BPA术。推荐意见3:开展BPA手术,需要配备导管室、血管造影机、常用血管介入器械和耗材、药品及抢救设备等。推荐意见4:应根据患者心肺功能、凝血功能和合并症情况综合判断,把握BPA适应证和禁忌证,确定最佳的BPA手术时机,提高手术安全性。推荐意见5:对于有经验的中心,如果从临床和影像特征判断为CTEPH,且D-二聚体不高,评估认为能从早期BPA中获益者,可以不经过3个月抗凝治疗。推荐意见6:BPA是一项较复杂的介入手术,需做好充分的术前评估和准备工作。推荐意见7:BPA围手术期抗凝药物的使用需要术者综合评估术中出血风险,个体化决策。推荐意见8:BPA有多种静脉入路选择,为便于操作和减少辐射暴露,在没有禁忌的情况下首选右侧股静脉。推荐意见9:CTEPH血管病变类型较多,为减少并发症,提高手术安全。一般情况下,宜优先处理环形狭窄、网状病变和次全闭塞病变,再处理完全闭塞和迂曲病变。推荐意见10:BPA对靶血管病变采用分次逐级球囊扩张策略。推荐意见11:肺动脉腔内OCT、IVUS成像技术可以帮助精确测定血管直径,并判断导丝是否位于血管真腔内。压力导丝能够准确客观判断扩张效果,在BPA术中运用具有一定价值。推荐意见12:BPA的治疗终点应个体化评估,包括临床症状、肺血流动力学、运动耐量及生活质量的改善。推荐意见13:BPA术后常规行生命体征监护,术中无明显并发症发生者术后尽早启动抗凝治疗。术中发生咯血者,术后根据咯血情况调整抗凝方案。推荐意见14:BPA术中、术后患者出现再灌注肺水肿时,应充分给氧,适度利尿,必要时使用无创正压通气治疗,严重病例需要尽早行有创呼吸机辅助通气或ECMO救治。推荐意见15:BPA术中出现咯血时,建议使用球囊堵塞阻断血流以及鱼精蛋白中和普通肝素。如果持续出血可选择明胶海绵、弹簧圈栓塞或植入覆膜支架。确保咯血停止后方可撤出球囊、导丝和指引导管。推荐意见16:BPA术中造影时,建议使用非离子型低渗或等渗对比剂,根据患者病情、心肾功能及术中对比剂用量决定是否水化。.